

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	7
1. Background.....	9
2. Objective and Scope.....	9
3. Selection of Topics for Monographs	10
4. Data for Monographs	11
5. The Working Group	11
6. Working Procedures	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	20
11. Summary of Data Reported	22
12. Evaluation.....	23
13. References.....	27
GENERAL REMARKS.....	33
THE MONOGRAPHS.....	49
Tobacco smoke	51
1. Production, Composition, Use and Regulations.....	53
1.1 Production and trade	53
1.1.1 History.....	53
1.1.2 World production and trade	54
1.1.3 What is produced	56
1.2 Composition	59
1.2.1 Cigarette tobacco	60
(a) Occurrence of tobacco-specific carcinogens and their precursors in tobacco	60
(b) The significance of the content of preformed TSNA precursors in tobacco	64
(c) TSNA-reduced tobacco	65

	(d) The origin of TSNA in tobacco smoke	65
	(e) The occurrence of volatile <i>N</i> -nitrosamines and non-volatile <i>N</i> -nitrosamino acids and other toxic compounds in tobacco	67
1.2.2	Mainstream cigarette smoke	68
	(a) Nicotine, tar and CO yields and other components in cigarette smoke	69
	(b) The emissions of nicotine and carcinogens in mainstream smoke: international comparison	80
	(c) Other constituents of cigarette smoke	88
1.2.3	Roll-your-own cigarettes	89
1.2.4	De-nicotinized cigarettes	90
1.2.5	Cigars	90
1.2.6	Pipe tobacco	93
1.2.7	Other products	93
1.2.8	Novel potentially reduced-exposure products	94
1.3	Use of tobacco	95
	(a) Surveys of smoking behaviour	97
	(b) Other indices of dose in developing countries and future surveillance needs	100
1.4	Regulations	100
	(a) Price/excise taxes	103
	(b) Restricting tobacco advertising and promotion	103
	(c) Restricting the uptake of tobacco use by young people	104
	(d) Regulation and litigation	105
	(e) Regulation of tobacco smoke constituents	105
	References	106
2.	Studies of Cancer in Humans	121
	Description of cohort studies	121
	(a) Europe	121
	(b) North America	126
	(c) Asia	132
	(d) Others	135
	References	151
2.1	Cigarette smoking	161
	2.1.1 Lung cancer	161
	(a) Factors affecting risk	161
	(b) Population characteristics	172
	(c) Lifetime probability that a smoker will develop lung cancer	174
	References	264
	2.1.2 Cancer of the lower urinary tract	275

(a) Analytical studies.....	275
(b) Population characteristics	277
(c) Pooled analysis.....	278
References	333
2.1.3 Renal-cell carcinoma	339
References	354
2.1.4 Upper aerodigestive tract	357
(a) Oral cancer.....	357
(b) Sinonasal cancer.....	359
(c) Nasopharyngeal carcinoma	360
(d) Cancer of the pharynx	361
(e) Cancer of the oesophagus	362
(f) Cancer of the larynx.....	364
(g) Cancer of the upper aerodigestive tract.....	366
References	508
2.1.5 Cancer of the pancreas	519
(a) Cohort and case-control studies	519
(b) Factors affecting risk	519
(c) Population characteristics	520
(d) Confounding factors.....	520
References	553
2.1.6 Cancer of the stomach	557
(a) Cohort studies	557
(b) Case-control studies	558
(c) <i>Helicobacter pylori</i> infection.....	560
(d) Precursor lesions	561
References	609
2.1.7 Colorectal cancer	615
(a) Overview	615
(b) Factors affecting risk	615
(c) Population characteristics	619
(d) Subsites of colorectal cancer	619
(e) Confounding.....	620
(f) Colorectal polyps	621
References	672
2.1.8 Cancer of the liver	679
(a) Overall risk.....	679
(b) Factors affecting risk	681
(c) Population characteristics	682
References	706
2.1.9 Breast cancer.....	711
References	737

2.1.10	Cervical cancer	743
	References	787
2.1.11	Endometrial cancer	793
	References	809
2.1.12	Prostate cancer	813
	References	818
2.1.13	Leukaemia	821
	References	831
2.1.14	Other organs	833
	(a) Cancer of the salivary gland	833
	(b) Cancer of the small intestine	833
	(c) Cancers of the gallbladder and extra-hepatic bile ducts ...	833
	(d) Soft-tissue sarcoma	835
	(e) Skin cancer	835
	(f) Ovarian cancer	835
	(g) Testicular cancer	835
	(h) Cancer of the central nervous system	836
	(i) Thyroid cancer	836
	(j) Cancer of the adrenal gland	836
	(k) Lymphoma	836
	(l) Multiple myeloma	837
	References	840
2.2	Pipe, cigar, bidi and other tobacco smoking	845
2.2.1	Pipe and cigar smoking	845
	(a) Introduction	845
	(b) Cancer of the lip, oral cavity and pharynx	845
	(c) Lung cancer	848
	(d) Laryngeal cancer	849
	(e) Oesophageal cancer	850
	(f) Stomach cancer	851
	(g) Colorectal cancer	851
	(h) Cancer of the liver and intrahepatic bile ducts	852
	(i) Cancer of the gallbladder and extrahepatic bile ducts	852
	(j) Cancer of the pancreas	852
	(k) Cancer of the bladder and kidney	853
	(l) Prostate cancer	853
	(m) Cancer of the haematopoietic system	854
	(n) Cancer of other organs	854
2.2.2	Bidi and other tobacco smoking	854
	(a) Introduction	854
	(b) Cancer of the oral cavity and pharynx	855
	(c) Lung cancer	860

(d) Laryngeal cancer	861
(e) Oesophageal cancer	862
(f) Stomach cancer	863
References	907
2.3 Synergistic carcinogenic effects of tobacco smoke and other carcinogens	913
2.3.1 Introduction	913
(a) Epidemiological concepts	914
(b) Statistical concepts	915
(c) Characterizing the burden of cancer attributable to smoking	916
2.3.2 Asbestos	917
2.3.3 Radon and other ionizing radiation	919
2.3.4 Arsenic	922
2.3.5 Alcohol drinking	922
(a) Cancers of the upper aerodigestive tract	922
(b) Liver cancer	923
2.3.6 Infectious agents	923
(a) Hepatitis B	923
(b) Human papillomavirus	923
(c) <i>Helicobacter pylori</i>	924
2.3.7 Others	924
(a) Nickel	924
(b) Silica (silicon dioxide)	924
(c) Chloromethyl ethers	924
References	963
3. Carcinogenicity Studies in Experimental Animals	973
3.1 Inhalation exposure: mainstream tobacco smoke	973
3.1.1 Mouse	977
3.1.2 Rat	979
3.1.3 Syrian hamster	981
3.1.4 Rabbit	983
3.1.5 Dog	983
3.2 Inhalation exposure in conjunction with administration of known carcinogens and other agents	984
3.2.1 Mouse	984
(a) 4-(<i>N</i> -Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	984
(b) Influenza virus	985
3.2.2 Rat	985
(a) Benzo[<i>a</i>]pyrene	985
(b) Chrysotile	988
(c) Radon progeny	988

	(d) Plutonium oxide	988
3.2.3	Syrian hamster	989
	(a) Benzo[<i>a</i>]pyrene	989
	(b) Blue Cape asbestos	989
	(c) 7,12-Dimethylbenz[<i>a</i>]anthracene.....	989
	(d) 4-(<i>N</i> -Nitrosomethylamino)-1-(3-pyridyl)-1-butanone	990
	(e) <i>N</i> -Nitrosobis(2-oxopropyl)amine.....	990
	(f) <i>N</i> -Nitrosodiethylamine.....	990
3.2.4	Dog	991
3.3	Administration of tobacco-smoke condensate	991
3.3.1	Skin application	994
	(a) Mouse.....	994
	(b) Rat	996
	(c) Syrian hamster	996
	(d) Rabbit.....	996
3.3.2	'Initiation-promotion' skin painting studies	996
3.3.3	Topical application to oral mucosa.....	997
3.3.4	Intrapulmonary administration	997
	(a) Rat	997
	(b) Hamster	998
3.3.5	Gavage study.....	998
	References.....	999
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	1005
4.1	Absorption, distribution, metabolism and excretion.....	1005
4.1.1	Humans	1005
	(a) Introduction	1005
	(b) Effects of tobacco smoke on human enzyme activities and metabolism	1009
	(c) Biomarkers of tobacco smoke carcinogens	1012
4.1.2	Experimental systems	1070
	(a) Effects of tobacco smoke on enzyme activities.....	1070
	(b) Biomarkers of tobacco smoke carcinogens	1075
	(c) Other data.....	1080
4.2	Toxic effects	1081
4.2.1	Humans	1081
	(a) Nicotine addiction	1081
	(b) Health effects other than cancer	1082
4.2.2	Animals.....	1084
	(a) Nicotine addiction/dependence	1084
	(b) Other effects in experimental animals	1085
4.3	Reproductive and hormonal effects	1090

4.3.1	Humans	1090
	(a) Reproductive effects	1090
	(b) Hormonal effects	1092
4.3.2	Animals	1097
	(a) Reproductive and perinatal effects	1097
	(b) Hormonal effects	1100
4.4	Genetic and related effects	1103
4.4.1	Humans	1103
	(a) Mutagenicity, sister chromatid exchanges, <i>HPRT</i> mutation and other effects	1103
	(b) Mutations in <i>TP53</i> , <i>K-RAS</i> and related genes	1110
	(c) Influence of polymorphisms in carcinogen-metabolizing genes on smoking-associated biomarkers	1111
4.4.2	Experimental systems	1112
	(a) Genotoxic effects, mutagenicity of cigarette-smoke condensate, urinary mutagenicity and mutation spectra ..	1112
	(b) Cytogenetic effects of cigarette smoke and its condensate <i>in vitro</i>	1114
	(c) Cytogenetic effects of cigarette smoke <i>in vivo</i>	1114
	(d) DNA strand breaks	1115
	(e) Studies on cigarettes that primarily heat but not burn tobacco, and modified cigarettes	1115
	(f) Transplacental effects	1116
	(g) Modulation of genotoxicity of tobacco smoke and cigarette-smoke condensate	1116
4.5	Mechanistic considerations	1116
	References	1117
5.	Summary of data reported and evaluation	1179
5.1	Exposure data	1179
5.2	Human carcinogenicity data	1180
5.3	Animal carcinogenicity data	1185
5.4	Other relevant data	1185
5.5	Evaluation	1187
	Involuntary smoking	1189
1.	Composition, Exposure and Regulations	1191
1.1	Composition	1191
1.1.1	Secondhand smoke	1191
1.1.2	Exhaled mainstream smoke	1196
1.1.3	Sidestream smoke	1196

1.2	Exposure	1204
1.2.1	Measurements of nicotine and particulate matter in indoor air.....	1207
1.2.2	Population-based measurements of exposure.....	1208
	(a) Adults	1209
	(b) Children	1210
1.3	Regulations	1216
1.3.1	Policy options	1216
1.3.2	Prevalence of regulations	1216
1.3.3	Effectiveness of regulations	1222
	References.....	1223
2.	Studies of Cancer in Humans	1231
2.1	Lung cancer	1231
2.1.1	Cohort studies	1231
2.1.2	Case-control studies	1237
	(a) Description of studies	1237
	(b) Exposure to secondhand smoke from the partner	1254
	(c) Exposure to secondhand smoke at the workplace	1257
	(d) Exposure during childhood	1259
	(e) Exposure from other sources	1259
	(f) Bias and confounding	1261
2.1.3	Meta-analyses of observational studies of exposure to secondhand smoke and lung cancer in adults.....	1263
	(a) Introduction	1263
	(b) Published meta-analyses	1264
	(c) Updated meta-analyses	1269
2.2	Breast cancer	1271
2.2.1	Cohort studies	1271
2.2.2	Case-control studies	1280
2.3	Childhood cancers	1284
2.3.1	All sites combined	1285
2.3.2	Brain and central nervous system.....	1293
2.3.3	Leukaemias and lymphomas.....	1300
2.3.4	Other childhood cancers	1307
2.4	Other cancers.....	1308
2.4.1	All cancer sites combined.....	1308
2.4.2	Cervical cancer	1309
2.4.3	Gastrointestinal cancers	1310
2.4.4	Nasopharyngeal and nasal sinus cavity cancer.....	1310
2.4.5	Tumours of the brain and central nervous system	1312
	References.....	1312

3. Studies of Cancer in Experimental Animals.....	1323
3.1 Inhalation exposure: simulated environmental tobacco smoke	1323
3.2 Administration of condensates of sidestream smoke	1329
3.2.1 Mouse	1329
3.2.2 Rat.....	1329
3.3 Observational studies of cancer in companion animals	1330
3.3.1 Case reports.....	1330
3.3.2 Case-control studies	1330
(a) Dog.....	1330
(b) Cat	1332
References.....	1332
4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	1335
4.1 Absorption, distribution, metabolism and excretion.....	1335
4.1.1 Humans	1335
(a) Enzyme activities and metabolism	1335
(b) Tobacco smoke carcinogen biomarkers.....	1335
(c) Other biomarkers	1341
(d) Nicotine and its metabolites as biomarkers	1343
4.1.2 Experimental systems	1347
(a) Effects of tobacco smoke on enzyme activities.....	1347
(b) Tobacco smoke carcinogen biomarkers.....	1353
(c) Other biomarkers and metabolites	1357
4.2 Toxic effects	1358
4.2.1 Humans	1358
(a) Nicotine addiction	1358
(b) Cardiovascular system	1358
(c) Respiratory system.....	1362
4.2.2 Experimental systems	1366
(a) Exposure of adult animals	1366
(b) Effects of perinatal exposure	1371
4.3 Reproductive, developmental and hormonal effects.....	1374
4.3.1 Humans	1374
(a) Reproductive effects	1374
(b) Body weight.....	1375
(c) Hormones.....	1376
(d) Menopause	1376
4.3.2 Experimental systems	1376
4.4 Genetic and related effects	1377
4.4.1 Humans.....	1377
(a) Mutagenicity, sister chromatid exchange and <i>HPRT</i> mutations	1377

(b) Mutations in <i>TP53</i> , <i>KRAS</i> and related genes.....	1380
(c) Polymorphisms in xenobiotic metabolizing genes	1381
4.4.2 Experimental systems	1381
(a) In-vitro studies on genotoxicity	1381
(b) In-vivo studies on genotoxicity	1381
4.5 Mechanistic considerations	1382
References.....	1383
5. Summary of Data Reported and Evaluation.....	1409
5.1 Exposure data	1409
5.2 Human carcinogenicity data	1409
5.3 Animal carcinogenicity data	1411
5.4 Other relevant data	1411
5.5 Evaluation	1413
LIST OF ABBREVIATIONS USED IN THIS VOLUME	1415
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES.....	1419

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.